Monitor upcoming data presentations at AUA (May 15) and ISSVA (May 20) for TARA-002 in NMIBC and LMs, as positive results could drive near-term upside. Additionally, THRIVE-3 interim results in 2H 2026 represent a key catalyst for IV Choline Chloride.
Price Chart
Executive Summary
Protara Therapeutics reported Q1 2026 net loss of $0.31 per share, beating consensus estimates of $0.37 loss, with cash of $177.4M to fund operations into 2028. Pipeline progress includes planned BLA submission for TARA-002 in lymphatic malformations in 2H 2027 and multiple data presentations in May 2026.
Key Financial Metrics
Key Facts
- Q1 2026 net loss $17.8M ($0.31/share) vs consensus $0.37 loss per share
- Cash, equivalents and marketable securities $177.4M as of March 31, 2026
- Plan to submit BLA for TARA-002 in LMs in 2H 2027
- Enrollment completion for BCG-Unresponsive cohort in ADVANCED-2 trial expected 2H 2026
- Interim results for THRIVE-3 (IV Choline Chloride) expected 2H 2026
- Research and development expenses increased to $13.6M from $9.1M in prior year period
Financial Impact
Net loss per share improved 16.2% versus consensus; cash burn rate increased with R&D expenses up 48% YoY
Risk Factors
- Clinical trial enrollment delays or negative data readouts
- Cash burn rate may require future capital raises before BLA submission
- Regulatory setbacks for TARA-002 BLA or THRIVE-3
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3293938 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 11, 2026 7w ago | 8-K | $3.91 $3.83 | ▼ −2.05% | ▼ −0.99% | $2.70 (−30.95%) |
Aug 11, 2026 7w ago | Press Release | $3.91 $3.83 | ▼ −2.05% | ▼ −0.99% | $2.70 (−30.95%) |
Jun 29, 2026 13w ago | 8-K | $3.82 $4.04 | ▲ +5.76% | ▲ +6.79% | $2.70 (−29.32%) |
May 26, 2026 18w ago | EFFECT | $4.80 $4.06 | ▲ +15.52% | ▲ +13.57% | $2.70 (+43.75%) |
May 15, 2026 20w ago | Press Release | $5.10 $3.94 | ▼ −22.75% | ▼ −24.86% | $2.70 (−47.06%) |
May 13, 2026 20w ago | 8-K | $5.20 $3.65 | ▼ −29.81% | ▼ −29.19% | $2.70 (−48.08%) |
May 13, 2026 20w ago | Press Release | $5.20 $3.65 | ▼ −29.81% | ▼ −29.19% | $2.70 (−48.08%) |
Apr 28, 2026 22w ago | DEFA14A | $5.17 $4.75 | ▼ −8.12% | ▼ −14.17% | $2.70 (−47.78%) |
Mar 10, 2026 29w ago | Press Release | $5.71 $5.22 | ▼ −8.58% | ▼ −8.43% | $2.70 (−52.71%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access